journal
MENU ▼
Read by QxMD icon Read
search

Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders

journal
https://www.readbyqxmd.com/read/29779197/cardiac-versus-non-cardiac-related-mortality-following-percutaneous-coronary-intervention-in-patients-with-insulin-treated-type-2-diabetes-mellitus-a-meta-analysis
#1
Qiang Wang, Hao Liu, Jiawang Ding
INTRODUCTION: Cardiovascular mortality is a major concern for patients with type 2 diabetes mellitus (T2DM). Insulin therapy significantly contributes to a high rate of death in these patients. We have performed a meta-analysis comparing cardiac and non-cardiac-related mortality following percutaneous coronary intervention (PCI) in a sample of patients with insulin-treated type 2 diabetes mellitus (ITDM). METHODS: Studies were included in the meta-analysis if: (1) they were trials or cohort studies involving patients with T2DM post-PCI; (2) the outcomes in ITDM were separately reported; and (3) they reported cardiac death and non-cardiac death among their clinical endpoints...
May 19, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29779196/retrospective-analysis-of-an-insulin-to-liraglutide-switch-in-patients-with-type-2-diabetes-mellitus
#2
Eveline Bruinstroop, Laura Meyer, Catherine B Brouwer, Diana E van Rooijen, P Sytze van Dam
INTRODUCTION: Insulin and the GLP-1 receptor agonist liraglutide are both effective in reaching glycemic targets. The efficacy of an insulin-to-liraglutide switch in an obese population with concurrent use of sulfonylurea and metformin is unknown. We assessed the efficacy and determinants of success of an insulin-to-liraglutide switch in these patients. METHODS: In a retrospective study we analyzed all patients that underwent an insulin-to-liraglutide switch during routine medical care (January 2009-February 2015)...
May 19, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29779195/efficacy-and-safety-of-alirocumab-in-individuals-with-diabetes-mellitus-pooled-analyses-from-five-placebo-controlled-phase-3-studies
#3
Henry N Ginsberg, Michel Farnier, Jennifer G Robinson, Christopher P Cannon, Naveed Sattar, Marie T Baccara-Dinet, Alexia Letierce, Maja Bujas-Bobanovic, Michael J Louie, Helen M Colhoun
INTRODUCTION: Diabetes mellitus (DM) carries an elevated risk for cardiovascular disease. Here, we assessed alirocumab efficacy and safety in people with/without DM from five placebo-controlled phase 3 studies. METHODS: Data from up to 78 weeks were analyzed in individuals on maximally tolerated background statin. In three studies, alirocumab 75 mg every 2 weeks (Q2W) was increased to 150 mg Q2W at week 12 if week 8 low-density lipoprotein cholesterol (LDL-C) was ≥ 70 mg/dL; two studies used alirocumab 150 mg Q2W throughout...
May 19, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29761289/prevalence-and-risk-factors-for-diabetes-mellitus-in-nigeria-a-systematic-review-and-meta-analysis
#4
Andrew E Uloko, Baba M Musa, Mansur A Ramalan, Ibrahim D Gezawa, Fabian H Puepet, Ayekame T Uloko, Musa M Borodo, Kabiru B Sada
INTRODUCTION: There has been no nationwide health (diabetes) survey in Nigeria since 1992, when a diabetes mellitus (DM) prevalence of 2.2% was reported. We aimed to determine the prevalence of and risk factors for DM in Nigeria by performing a systematic review and meta-analysis. METHODS: We searched Medline, EMBASE, PubMed, PapersFirst, the Cochrane Library, Scopus, Bioline, African Journals Online, Institute of Scientific Information, and Google Scholar from the year 1990 to 2017...
May 14, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29754323/the-effects-of-exenatide-and-metformin-on-endothelial-function-in-newly-diagnosed-type-2-diabetes-mellitus-patients-a-case-control-study
#5
Yanjin Hu, Jia Liu, Guang Wang, Yuan Xu
INTRODUCTION: Exenatide is a new antidiabetic glucagon-like peptide-1 receptor agonist. In addition to its hypoglycemic effect, exenatide may have a potential protective benefit on vascular endothelial function. This study attempted to compare the effects of exenatide and traditional antidiabetic drug metformin treatment on endothelial function in overweight patients with type 2 diabetes. METHODS: Ninety overweight patients with newly diagnosed type 2 diabetes were recruited; 45 patients received exenatide (Exe) treatment and 45 patients received metformin (Met) treatment for 12 weeks...
May 12, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29744822/study-protocol-for-the-initial-choice-of-dpp-4-inhibitor-in-japanese-patients-with-type-2-diabetes-mellitus-effect-of-linagliptin-on-qol-intel-qol-trial
#6
Tomoya Mita, Toru Hiyoshi, Hidenori Yoshii, Hiroko Chimori, Kazuo Ikeda, Junko Sato, Hirotaka Watada
INTRODUCTION: Consideration of treatment-related quality of life (QOL) is important in diabetes management. However, no studies have compared the influence of dipeptidyl peptidase-4 inhibitors versus metformin on treatment-related QOL when used as first-line therapy in patients with type 2 diabetes mellitus. METHODS: This study is a prospective, randomized, open-label, multicenter, parallel-group, comparative study. Between June 2016 and December 2017, 44 participants who failed to achieve glycemic control despite diet and exercise therapy were recruited at 14 clinics and randomly allocated to linagliptin or metformin therapy...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29744821/thoughts-words-action-the-alma-ata-declaration-to-diabetes-care-transformation
#7
EDITORIAL
Sanjay Kalra, Zhanay A Akanov, Alex Y Pleshkova
The International Conference on Primary Health Care, held at Alma-Ata, present-day Kazakhstan, in September 1978, was a landmark in global health care. The Declaration of Alma-Ata that was adopted at that conference successfully refocused attention and energy on primary health care. In a similar manner, the United Nations resolution of 2006 highlighted the dangers of the diabetes pandemic. The underlying philosophy of the Declaration of Alma-Ata is assessed in this editorial, to determine whether it remains relevant for modern and future diabetes care...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29744820/artificial-pancreas-as-an-effective-and-safe-alternative-in-patients-with-type-1-diabetes-mellitus-a-systematic-review-and-meta-analysis
#8
Xia Dai, Zu-Chun Luo, Lu Zhai, Wen-Piao Zhao, Feng Huang
INTRODUCTION: Insulin injection is the main treatment in patients with type 1 diabetes mellitus (T1DM). Even though continuous glucose monitoring has significantly improved the conditions of these patients, limitations still exist. To further enhance glucose control in patients with T1DM, an artificial pancreas has been developed. We aimed to systematically compare artificial pancreas with its control group during a 24-h basis in patients with T1DM. METHODS: Electronic databases were carefully searched for English publications comparing artificial pancreas with its control group...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29744819/comparison-of-glycemic-variability-in-chinese-t2dm-patients-treated-with-exenatide-or-insulin-glargine-a-randomized-controlled-trial
#9
Ting-Ting Yin, Yan Bi, Ping Li, Shan-Mei Shen, Xiao-Lu Xiong, Li-Jun Gao, Can Jiang, Yan Wang, Wen-Huan Feng, Da-Long Zhu
INTRODUCTION: Increasing the frequency of blood glucose monitoring aids the evaluation of glycemic variability and blood glucose control by antidiabetic drugs. It remains unclear, however, whether GLP-1 receptor agonists or basal insulin has a better effect on glycemic variability in type 2 diabetes mellitus (T2DM) patients who are inadequately controlled by metformin. We used a continuous glucose monitoring system (CGMS) to compare patients on a GLP-1 receptor agonist with patients on basal insulin in terms of glycemic variability...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29744818/real-world-clinical-effectiveness-and-cost-savings-of-liraglutide-versus-sitagliptin-in-treating-type-2-diabetes-for-1-and-2-years
#10
Qian Li, Rahul Ganguly, Michael L Ganz, Cory Gamble, Tam Dang-Tan
INTRODUCTION: This study compared the clinical and economic outcomes of long-term use of liraglutide versus sitagliptin for the treatment of type 2 diabetes (T2DM) in real-world practice in the USA. METHODS: We identified adult patients (≥ 18 years old) with T2DM who initiated liraglutide or sitagliptin in 2010-2014 using a large claims database. Quarterly glycemic control measures and annual healthcare costs were assessed during the 1st and 2nd years of persistent medication use...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29725970/predominant-improvement-of-alpha-cell-function-after-steroid-therapy-in-a-patient-with-autoimmune-pancreatitis-case-report
#11
Ken Takeshima, Hiroyuki Ariyasu, Hiroshi Iwakura, Shintaro Kawai, Shinsuke Uraki, Hidefumi Inaba, Machi Furuta, Kenji Warigaya, Shin-Ichi Murata, Takashi Akamizu
INTRODUCTION: Autoimmune pancreatitis (AIP) is a subset of inflammatory pancreatic disease, responsive to corticosteroid therapy. It is prone to being affected by diabetes mellitus, but the effectiveness of steroid therapy on pancreatic endocrine function is still controversial. We present a case of AIP, focusing on pancreatic endocrine function after steroid therapy. CASE REPORT: The patient was referred to our hospital with exacerbation of diabetic control and pancreatic swelling...
May 3, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29725969/differences-in-glycemic-control-in-diabetic-and-non-diabetic-patients-with-parenteral-nutrition-using-a-basal-plus-correction-insulin-regimen-an-observational-retrospective-study
#12
Analía Ramos, Fernanda Rabasa, Lilian Mendoza, Joana Cardenete, Pedro Gill, Alba Morilla, Daniel Cardona, Antonio Pérez
INTRODUCTION: Hyperglycemia is a frequent complication of parenteral nutrition (PN) in patients both with and without diabetes mellitis (DM). The aim of this study was to evaluate the quality of glucose control achieved with basal plus-correction insulin in surgical patients with and without a history of DM receiving PN. METHODS: Retrospective evaluation of a protocol applied during the period of January 2013-December 2015. The insulin dose was started at 0.4 and 0...
May 3, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29713962/devote-5-evaluating-the-short-term-cost-utility-of-insulin-degludec-versus-insulin-glargine-u100-in-basal-bolus-regimens-for-type-2-diabetes-in-the-uk
#13
Richard F Pollock, William J Valentine, Steven P Marso, Jens Gundgaard, Nino Hallén, Lars L Hansen, Deniz Tutkunkardas, John B Buse
INTRODUCTION: The aim of this study was to evaluate the short-term cost-utility of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) for the treatment of type 2 diabetes in the basal-bolus subgroup of the head-to-head cardiovascular (CV) outcome trial, DEVOTE. METHODS: A cost-utility analysis was conducted over a 2-year time horizon using a decision analytic model to compare costs in patients receiving once daily degludec or glargine U100, both as part of a basal-bolus regimen, in addition to standard care...
April 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29713961/a-systematic-literature-review-and-network-meta-analysis-comparing-once-weekly-semaglutide-with-other-glp-1-receptor-agonists-in-patients-with-type-2-diabetes-previously-receiving-basal-insulin
#14
Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazic
INTRODUCTION: Once-weekly semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently available as 1.0 mg and 0.5 mg dose for the treatment of type 2 diabetes (T2D). Currently, no head-to-head trial investigating once-weekly semaglutide as an add-on to basal insulin vs other GLP-1 receptor agonists (GLP-1 RAs) is available. The aim of this study was to conduct a network meta-analysis (NMA) to assess the efficacy and safety of once-weekly semaglutide vs other GLP-1 RAs in patients with T2D inadequately controlled on basal insulin...
April 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29700772/cost-effectiveness-of-insulin-degludec-versus-insulin-glargine-u100-in-patients-with-type-1-and-type-2-diabetes-mellitus-in-serbia
#15
Nebojša Lalić, Monika Russel-Szymczyk, Marina Culic, Christian Klyver Tikkanen, Barrie Chubb
INTRODUCTION: This study investigates the cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes mellitus in Serbia. METHODS: A cost-utility analysis, implementing a simple short-term model, was used to compare treatment costs and outcomes with degludec versus glargine U100 in patients with type 1 (T1DM) and type 2 diabetes (T2DM). Cost-effectiveness was analysed in a 1-year setting, based on data from clinical trials...
April 26, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29696567/factors-influencing-the-prescribing-preferences-of-physicians-for-drug-naive-patients-with-type-2-diabetes-mellitus-in-the-real-world-setting-in-japan-insight-from-a-web-survey
#16
Hiroki Murayama, Kota Imai, Masato Odawara
INTRODUCTION: The Japanese guidelines for type 2 diabetes mellitus (T2DM) emphasize individualization of treatment based on patient need and encourage physicians to select an appropriate oral antidiabetes drug (OAD). However, limited evidence is available on the factors influencing the selection by physicians (diabetes specialists and nonspecialists) of the first-line OAD to treat drug-naive patients with T2DM. A survey was designed to explore the treatment factors and patient characteristics that influence physicians when they choose an initial OAD to prescribe to a drug-naive patient with T2DM in a real-world setting in Japan...
April 25, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29675798/a-systematic-literature-review-and-network-meta-analysis-comparing-once-weekly-semaglutide-with-other-glp-1-receptor-agonists-in-patients-with-type-2-diabetes-previously-receiving-1-2-oral-anti-diabetic-drugs
#17
Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazic
INTRODUCTION: Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1-2 oral anti-diabetic drugs (OADs) vs other GLP-1 receptor agonists (GLP-1 RAs) are limited, a network meta-analysis (NMA) was performed. The objective was to assess the relative efficacy and safety of once-weekly semaglutide vs GLP-1 RAs in patients with type 2 diabetes (T2D) inadequately controlled on 1-2 OADs...
April 19, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29675797/treatment-intensification-in-type-2-diabetes-a-real-world-study-of-2-oad-regimens-glp-1-ras-or-basal-insulin
#18
Lawrence Blonde, Denis Raccah, Elisheva Lew, Juliana Meyers, Elena Nikonova, Mayank Ajmera, Keith L Davis, Monica Bertolini, Bruno Guerci
INTRODUCTION: Treatment guidelines recommend a stepwise approach to glycemia management in patients with type 2 diabetes (T2D), but this may result in uncontrolled glycated hemoglobin A1c (HbA1c) between steps. This retrospective analysis compared clinical and economic outcomes among patients with uncontrolled T2D initiating two oral antidiabetes drugs (OADs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or basal insulin in a real-world setting. METHODS: Adults with T2D on OAD monotherapy were identified in the MarketScan claims database (2007-2014)...
April 19, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29667107/a-computer-based-glucose-management-system-reduces-the-incidence-of-forgotten-glucose-measurements-a-retrospective-observational-study
#19
Tsuyoshi Okura, Kei Teramoto, Rie Koshitani, Yohei Fujioka, Yusuke Endo, Masaru Ueki, Masahiko Kato, Shin-Ichi Taniguchi, Hiroshi Kondo, Kazuhiro Yamamoto
INTRODUCTION: Frequent glucose measurements are needed for good blood glucose control in hospitals; however, this requirement means that measurements can be forgotten. We developed a novel glucose management system using an iPod® and electronic health records. METHODS: A time schedule system for glucose measurement was developed using point-of-care testing, an iPod® , and electronic health records. The system contains the glucose measurement schedule and an alarm sounds if a measurement is forgotten...
April 17, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29663262/characteristics-treatment-patterns-and-economic-outcomes-of-patients-initiating-injectable-medications-for-management-of-type-2-diabetes-mellitus-in-japan-results-from-a-retrospective-claims-database-analysis
#20
Shuichi Suzuki, Urvi Desai, Alena Strizek, Jasmina Ivanova, Viviana Garcia-Horton, Zhihong Cai, Luke Schmerold, Xinyue Liu, Magaly Perez-Nieves
INTRODUCTION: This study's objective was to describe characteristics, treatment patterns, and economic outcomes of type 2 diabetes mellitus (T2DM) patients initiating injectable antidiabetic medications in Japan. METHODS: Adults (≥ 18 years) with T2DM, ≥ 2 claims for injectable antidiabetics between 1 August 2011 and 31 July 2015 (first claim = index date), no evidence of type 1 diabetes mellitus, ≤ 1 claim for insulin, no claims for GLP-1RA before index, and continuous enrollment for 6 months before (baseline) and 12 months after index (follow-up) were selected from the Japan Medical Center Database...
April 16, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
journal
journal
43222
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"